Susceptibility surveillance among gram-negative bacilli at a cancer center

被引：33

作者：

Jacobson, K ^{[1
]}

Rolston, K ^{[1
]}

Elting, L ^{[1
]}

LeBlanc, B ^{[1
]}

Whimbey, E ^{[1
]}

Ho, DH ^{[1
]}

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Infect Dis Sect, Houston, TX 77030 USA

来源：

CHEMOTHERAPY | 1999年 / 45卷 / 05期

关键词：

gram-negative bacilli; resistance; increasing; antimicrobial;

D O I：

10.1159/000007223

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

We conducted a survey of susceptibility among 758 gram-negative bacilli (GNB; collected from cancer patients over a 3-month period) to commonly used antibiotics. The overall resistance among GNB was least for piperacillin/tazobactam and meropenem (5 and 6%, respectively) followed by cefepime (8%), imipenem (9%), amikacin (12%), ofloxacin (13%), ciprofloxacin, ceftazidime and ticarcillin/clavulanate (14% each), aztreonam (18%) and tobramycin (24%). In comparison to data on antibiotic resistance to ceftazidime, imipenem, ciprofloxacin and aztreonam in similar studies in 1985 and 1994, resistance has significantly increased to all four antibiotic classes. Based on our current study, meropenem, cefepime, imipenem and piperacillin/tazobactam would be the most appropriate choices in our institution for empiric therapy of GNB infections in febrile neutropenic patients.

引用

页码：325 / 334

页数：10

共 14 条

[1]

SURVEY OF ANTIBIOTIC SUSCEPTIBILITY AMONG GRAM-NEGATIVE BACILLI AT A CANCER HOSPITAL [J].

BODEY, GP ;

HO, DH ;

ELTING, L .

AMERICAN JOURNAL OF MEDICINE, 1988, 85 (1A) :49-51

[2]

BODEY GP, 1993, CLIN INFECT DIS S2, V17, P378

[3]

EMERGENCE OF QUINOLONE-RESISTANT ESCHERICHIA-COLI BACTEREMIA IN NEUTROPENIC PATIENTS WITH CANCER WHO HAVE RECEIVED PROPHYLACTIC NORFLOXACIN [J].

CARRATALA, J ;

FERNANDEZSEVILLA, A ;

TUBAU, F ;

CALLIS, M ;

GUDIOL, F .

CLINICAL INFECTIOUS DISEASES, 1995, 20 (03) :557-560

[4]

CORONADO VG, 1995, INFECT CONT HOSP EP, V16, P71

[5]

1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever [J].

Hughes, WT ;

Armstrong, D ;

Bodey, GP ;

Brown, AE ;

Edwards, JE ;

Feld, R ;

Pizzo, P ;

Rolston, KVI ;

Shenep, JL ;

Young, LS .

CLINICAL INFECTIOUS DISEASES, 1997, 25 (03) :551-573

[6]

THE RELATIONSHIP BETWEEN ANTECEDENT ANTIBIOTIC USE AND RESISTANCE TO EXTENDED-SPECTRUM CEPHALOSPORINS IN GROUP-I BETA-LACTAMASE-PRODUCING ORGANISMS [J].

JACOBSON, KL ;

COHEN, SH ;

INCIARDI, JF ;

KING, JH ;

LIPPERT, WE ;

IGLESIAS, T ;

VANCOUWENBERGHE, CJ .

CLINICAL INFECTIOUS DISEASES, 1995, 21 (05) :1107-1113

[7]

EMERGENCE OF FLUOROQUINOLONE-RESISTANT ESCHERICHIA-COLI AT A CANCER CENTER [J].

KERN, WV ;

ANDRIOF, E ;

OETHINGER, M ;

KERN, P ;

HACKER, J ;

MARRE, R .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (04) :681-687

[8]

MANAGEMENT OF THE CANCER-PATIENT WITH FEVER AND PROLONGED NEUTROPENIA [J].

LEE, JW ;

PIZZO, PA .

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1993, 7 (05) :937-960

[9]

MCGOWAN JE, 1983, REV INFECT DIS, V5, P1033

[10]

*NAT COMM CLIN LAB, 1990, M7AZ NAT COMM CLIN L

← 1 2 →